Search hospitals
>
Illinois
>
Macomb
Illinois CancerCare-Macomb
Claim this profile
Macomb, Illinois 61455
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
401 reported clinical trials
14 medical researchers
Summary
Illinois CancerCare-Macomb is a medical facility located in Macomb, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Illinois CancerCare-Macomb is involved with conducting 401 clinical trials across 476 conditions. There are 14 research doctors associated with this hospital, such as Bryan A. Faller, Ammar Sukari, Anthony F. Shields, and Anteneh A. Tesfaye.
Area of expertise
Lung Cancer
Illinois CancerCare-Macomb has run 75 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
Illinois CancerCare-Macomb has run 70 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
Ammar Sukari
Wayne State University/Karmanos Cancer Institute
3 years of reported clinical research
Anthony F. Shields
Barbara Ann Karmanos Cancer Institute
6 years of reported clinical research
Anteneh A. Tesfaye
Wayne State University/Karmanos Cancer Institute
6 years of reported clinical research
Clinical Trials running at Illinois CancerCare-Macomb
Lung Cancer
Prostate Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Breast cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Kidney Cancer
Colorectal Cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting
2 awards
Phase 3
14 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Macomb?
Illinois CancerCare-Macomb is a medical facility located in Macomb, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Illinois CancerCare-Macomb is involved with conducting 401 clinical trials across 476 conditions. There are 14 research doctors associated with this hospital, such as Bryan A. Faller, Ammar Sukari, Anthony F. Shields, and Anteneh A. Tesfaye.
Where is Illinois CancerCare-Macomb located?
Illinois CancerCare-Macomb is located at McLaren Macomb hospital, 1000 Harrington Ave, Mount Clemens, MI 48043. Henry Ford Cancer - Macomb Hospital can be found at 15855 19 Mile Road, Clinton Township, MI 48038.
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Macomb Hospital Financial Assistance and Insurance Contact Information:** **Financial Assistance:** - Credit Office: (309) 836-1528 **Insurance:** - Financial Services (Patient Billing): (309) 836-1524 For further financial support, CancerCare provides limited assistance for cancer-related costs (contact at 800-813-HOPE (4673)), and the Illinois Department of Healthcare and Family Services offers Medicaid and medical assistance programs for qualifying individuals.
What insurance does Illinois CancerCare-Macomb accept?
Illinois CancerCare-Macomb accepts a wide range of insurance plans such as Aetna Choice POS II, Aetna HMO, Aetna Managed Choice POS Open Access, Aetna Signature Administrators PPO, BCBS Blue Card PPO, and Medicare. Patients are advised to verify physician participation in their insurance plan and confirm if pre-certification is required. Co-payments are due at the time of visit, and patients are responsible for all charges incurred.
What awards or recognition has Illinois CancerCare-Macomb received?
Illinois CancerCare, with its Macomb location, stands out as a leading participant in clinical research, acknowledged by the Alliance for Clinical Trials in Oncology for its high enrollment rates. It has earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program, highlighting its commitment to the highest standards of outpatient hematology-oncology care. As central Illinois' largest network of cancer care specialists, Illinois CancerCare conducts around 100 open clinical cancer research trials at any given time.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.